Fractyl Health reported positive six-month trial results from an investigation of its Revita procedure last week, but shares of Fractyl stock dropped steeply on October 16 immediately following the announcement. Despite the positive findings, the stock’s sharp decline highlighted a contrast between the clinical findings and the market’s response.
Signos raised $20 million to expand its glucose monitoring platform for weight loss, which pairs Dexcom’s over-the-counter CGM with an app that translates glucose data into personalized diet and lifestyle recommendations.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
A new Nomi Health report found that GLP-1 use and spending among adolescents rose sharply from 2022 to 2025, raising concerns about future costs for self-insured employers.
Eli Lilly’s new Lilly Employer Connect platform offers employers more flexible access to obesity drugs like Zepbound, but experts say it represents only incremental progress.
GoodRx launched GoodRx Employer Direct, a program that allows employers to subsidize manufacturer-sponsored prices for high-cost brand medications like GLP-1s without adding them to their health insurance benefits.
Walgreens launched a virtual weight management program offering clinician support and GLP-1 prescriptions for self-pay patients.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
People like Oprah Winfrey have struggled to maintain their weight loss after weaning themselves off GLP-1s. What if an outpatient medtech procedure did the trick?
Jensen Huang, CEO of Nvidia and David Ricks, CEO of Eli Lilly, discussed their recently-announced partnership and the potential of GLP-1s at an event in San Francisco.
Berry Street's new GLP-1 nutrition program supports patients who are starting GLP-1s, currently taking them or transitioning off of them. Patients receive care from registered dietitians and certified nutrition specialists.
Noom recently launched a microdosing program for GLP-1s. However, some are concerned about the use of compounded GLP-1s in this program, as they are not FDA-approved.
What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes.